IRAK1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, considering that the combination of IRAK1/4 inhibitor and imatinib was effective at eliminating CML LSCs in the presence of T cell immunity, the negative effect of IRAK1/4 inhibitor may be minor in our experiments.